Opinion ID: 220774
Heading Depth: 3
Heading Rank: 2

Heading: BioScrip’s Tacrolimus Suspension

Text: Huerta had her tacrolimus prescription filled by BioScrip in April of 2006. BioScrip had compounded, or mixed, the liquid form of tacrolimus (called a “suspension”) by crushing tacrolimus capsules and mixing the resulting powder with a syrup according to recipes in the National Children’s Hospital Pharmacy Guide. The tacrolimus capsules were manufactured and distributed by Astellas Pharma U.S., Inc., a party dismissed from the instant case because there was no evidence that the tacrolimus Astellas manufactured and supplied to BioScrip was subpotent or had been the subject of a recall. BioScrip filled Huerta’s tacrolimus prescription from its Batch No. 37. Three other individuals also had their prescriptions filled from Batch No. 37. BioScrip did not receive any reports of error or of adverse reactions from those other three individuals.